Asthma

New England Journal of Medicine

Volumn 344, Issue 5, 2001, Pages 350-362

  Busse, William W ^a,b   Lemanske Jr , Robert F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRAKINCEPT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHEMOKINE; CORTICOSTEROID; CYTOKINE; DNA VACCINE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; THEOPHYLLINE; UNCLASSIFIED DRUG;

ALLERGY; ASTHMA; CYTOKINE PRODUCTION; DRUG EFFICACY; EOSINOPHIL; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOLOGY; INFLAMMATION; LUNG FUNCTION; MAST CELL; NEBULIZATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TH1 CELL; TH2 CELL;

ASTHMA; CHEMOKINES; CYTOKINES; EOSINOPHILS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTES; MAST CELLS; RESPIRATORY MECHANICS; TH1 CELLS; TH2 CELLS;

EID: 0035253291     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200102013440507     Document Type: Review

References (97)

1. The alliance of genes and environment in asthma and allergy
2. Transplacental priming of the human immune system to environmental allergens: Universal skewing of initial T cell responses toward the Th2 cytokine profile
3. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
4. Two subphenotypes of childhood asthma that differ in maternal and paternal influences on asthma risk
5. Occupational asthma
6. Inflammatory cell distribution within and along asthmatic airways
7. Alveolar tissue inflammation in asthma
8. Airway inflammation in mild intermittent and in persistent asthma
9. Molecular pathology of allergic disease. I. Lower airway disease
10. Cytokines in asthma
11. Transcription factors and asthma
12. The role of adhesion molecules in allergic inflammation and their suitability as targets of antiallergic therapy
13. Association of asthma with serum IgE levels and skin-test reactivity to allergens
14. The early and late response to allergen
15. Chemokines in nasal secretions of normal adults experimentally infected with respiratory syncytial virus
16. Interleukin-13: Central mediator of allergic asthma
17. Molecular mechanisms of immunoglobulin E regulation
18. Biochemical events in basophil or mast cell activation and mediator release
19. Complexity and redundancy in the pathogenesis of asthma: Reassessing the roles of mast cells and T cells
20. Mast cell effector mechanisms
21. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep
22. G protein variation in respiratory syncytial virus group A does not correlate with clinical severity
23. Late phase allergic reactions
24. Interleukin-5, eosinophils, and disease
25. Eosinophilia
26. Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge: Characterization of eosinophil and mast cell mediators
27. Interleukin-5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model
28. Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics
29. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
30. Cellular adhesion and its antagonism
31. Molecular basis for selective eosinophil trafficking in asthma: A multistep paradigm
32. Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation
33. Differential regulation of eosinophil adhesion and transmigration by pulmonary microvascular endothelial cells
34. Chemokines and allergic disease
35. Chemokines - Chemotactic cytokines that mediate inflammation
36. Expression of RANTES mRNA and protein in airways of patients with mild asthma
37. Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge
38. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics
39. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma: Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells
40. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma
41. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines
42. Gene expression of the GATA-3 transcription factor is increased in atopic asthma
43. H2-like bronchoalveolar T-lymphocyte population in atopic asthma
44. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia
45. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: Evidence against "intrinsic" asthma being a distinct immunopathologic entity
46. CD4 T-lymphocyte activation in acute severe asthma: Relationship to disease severity and atopic status
47. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma
48. Increased interferon-γ and tumor necrosis factor-α in bronchoalveolar lavage (BAL) fluid after antigen challenge in allergic subjects
49. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines
50. The one-two of T helper cells: Does interferon-gamma knock out the Th2 hypothesis for asthma?
51. Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma
52. A deficient capacity to produce interferon-gamma: Is it a risk for asthma and allergies?
53. Reduced interferon-gamma secretion in neonates and subsequent atopy
54. Hay fever, hygiene, and household size
55. The use of antibiotics in the first year of life and development of asthma: Which comes first?
56. The inverse association between tuberculin responses and atopic disorder
57. Measles and atopy in Guinea-Bissau
58. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus
59. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood
60. Maturation of immune responses at the beginning of asthma
61. Maternal programming in asthma and allergy
62. Family size, childhood infections and atopic diseases
63. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood: A prospective study
64. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma
65. Mite, cat, and cockroach exposure, allergen sensitisation, and asthma in children: A case-control study of three schools
66. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma
67. A 15-year follow-up study of ventilatory function in adults with asthma
68. Airway wall remodeling in asthma
69. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children
70. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma
71. Effect of early vs late intervention with inhaled corticosteroids in asthma
72. Small airway dimensions in asthma and in chronic obstructive pulmonary disease
73. A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema
74. Quantitative measurement of bronchial muscle in men with asthma
75. Computed tomography of the lungs in asthma: Influence of disease severity and etiology
76. Asthma and wheezing in the first six years of life
77. Mechanisms of action of glucocorticoids in asthma
78. Choosing a long-term controller medication in childhood asthma: The proverbial two-edged sword
79. Growth suppression by glucocorticoid therapy
80. Effect of inhaled formoterol and budesonide on exacerbations of asthma
81. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
82. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
83. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma
84. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
85. Airway and lung elastic fibre is not reduced in asthma nor in asthmatics following corticosteroid treatment
86. Effects of treatment of airway inflammation and thickening of basement membrane reticular collagen in asthma: A quantitative light and electron microscopic study
87. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma
88. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials
89. A controlled trial of immunotherapy for asthma in allergic children
90. Ragweed immunotherapy in adult asthma
91. DNA-based immunization for asthma
92. Oligonucleotide therapy of allergic asthma
93. Interleukin-4 receptor in moderate atopic asthma: A phase I/II randomized, placebo-controlled trial
94. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
95. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
96. Treatment of allergic asthma with monoclonal anti-IgE antibody